Bisu Raises $3.2M in Seed Round, Will Collaborate With ASICS on Future Projects

Funding to support launch of healthtech startup Bisu's 'lab-on-a-chip' urine and saliva analyzer

Bisu, Inc., a startup that helps people improve their health and wellness through lab-grade testing at home, today announced ­a new round of seed funding of $3.2 million. Leading the round was Korean biotech investor QUAD, with participation from ASI­CS Ventures Corporation, 15th Rock Ventures, Pacifico Investments, and SOSV, the world’s most active investor in hardware and health tech investing for the third time. The funding will enable Bisu to bring to market Bisu Body Coach, a portable “home health lab” for personalized nutrition and lifestyle advice through easy, accurate urine and saliva testing. Bisu also reached an agreement with ASICS Corporation to collaborate on health and fitness service initiatives.

Bisu Body Coach consists of a disposable test stick and a reader that syncs with a companion smartphone app. The microfluidic “lab-on-a-chip” technology used in the test stick enables reliable, precise and automated measurements of a wide range of biomarkers in just two minutes.

Bisu Body Coach app provides feedback on key nutrition indicators such as hydration, minerals and vitamins, and recommendations are personalized based on the user’s goals, dietary preferences, activity, sleep and weight. Bisu Body Coach is currently in beta, with a pipeline of additional test sticks covering training intensity, hormones, and pet and baby health. Bisu and ASICS will work together on future initiatives aimed to enhance personal health and athletic performance. ASICS’ investment follows Bisu’s victory in the U.S. Sports & Fitness Industry Association’s startup competition — one of the industry’s major events for which more than 100 sports and fitness executives served as judges.

“We decided to invest in Bisu because we believe its home health lab technology, which provides affordable access to actionable health data, is very innovative and has huge potential,” says Hiroaki Kageyama, President of ASICS Ventures. “We are thrilled to build this collaboration with Bisu as a strategic partner”.

“We’ve been flushing away insight and data for centuries,” says Duncan Turner, SOSV General Partner and HAX Managing Director. “Bisu is showing how valuable capturing and acting on that data can be for human health”.

“This funding is a major vote of confidence from a group of investors who are both tech-savvy, consumer-focused and globally minded,” says Daniel Maggs, Co-founder & CEO at Bisu. “We are delighted to announce our collaboration with ASICS. ASICS shares our passion for making beautiful yet scientifically rigorous products in the spirit of Japanese craftsmanship, yet is also a modern, globally-recognized brand,” says Wojciech Bula, PhD, Co-founder & CTO.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”